Obesity, heart and kidney diseases, and diabetes are all connected, and now that the American Heart Association has formalized CKM syndrome, it could change the future of cardiology.
The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern's Dr. Hans Hammers helps patients explore its benefits and risks.
Patients with kidney disease and living donors face new challenges in the wake of COVID-19. Get answers to pre- and post-transplant FAQs in this MedBlog.
